Core Viewpoint - The company has shown significant recovery in its financial performance following the divestiture of its IVD business, with a strong growth trajectory in revenue and net profit for the first three quarters of 2025 [1][2]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 186 million yuan, an increase of 17.45% year-on-year, and a net profit attributable to shareholders of 18 million yuan, up 362.49% [1]. - In Q3 2025, the company achieved revenue of 76 million yuan, reflecting a growth of 40.34%, and a net profit of 16 million yuan, which is a 187.43% increase [1]. Business Strategy and Developments - The impact of the IVD business divestiture has been fully realized, leading to a positive trend in overall performance. The company experienced a revenue decline of 63.01% and a net loss of 185 million yuan in 2023, but has since turned profitable in 2024 with a net profit of 17 million yuan [2]. - A significant overseas collaboration was established with global biotech giant Chr. Hansen, involving a five-year agreement worth 73.06 million euros (approximately 600 million yuan) for dairy product testing. This partnership is expected to drive future growth in international markets [3]. - The company is expanding its business in both B2B and B2G sectors, with notable collaborations in the cold chain and retail sectors, as well as successful bids for government projects in various provinces [4]. Future Outlook - The company anticipates continued growth, projecting net profits of 25 million yuan, 50 million yuan, and 70 million yuan for 2025 to 2027, with year-on-year growth rates of 44.9%, 100.3%, and 40.2% respectively [4]. - A DCF model estimates the company's overall valuation at 5.9 billion yuan, with a target price of approximately 15 yuan per share, maintaining a "recommended" rating [4].

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 15 yuan [2][8]. Core Insights - The company's performance trend is overall positive, with significant growth in revenue and net profit for the first three quarters of 2025. Revenue reached 186 million yuan, up 17.45% year-on-year, and net profit was 18 million yuan, up 362.49% year-on-year [2][8]. - The impact of the divestment of the IVD business is clearing, leading to a recovery in revenue growth and a significant increase in profit margins. The company expects continued growth driven by overseas expansion and new partnerships [8]. - The company has secured a major cooperation agreement with a global biotechnology giant, which is expected to enhance its overseas business and drive future revenue growth [8]. Financial Summary - For 2024A, total revenue is projected at 224 million yuan, with a year-on-year growth rate of -11.7%. By 2025E, revenue is expected to increase to 272 million yuan, reflecting a growth rate of 21.5% [4]. - The net profit for 2024A is estimated at 17 million yuan, with a significant increase to 25 million yuan in 2025E, representing a growth rate of 44.9% [4]. - The earnings per share (EPS) is projected to rise from 0.04 yuan in 2024A to 0.06 yuan in 2025E [4]. Business Development - The company is actively expanding its domestic and international business, with notable partnerships in the retail and food processing sectors. Collaborations with major clients like Hema Fresh and Kang Shifu are highlighted [8]. - The company is also pursuing government contracts in various provinces, enhancing its presence in the public sector [8].

Core Viewpoint - The article highlights the growth and strategic focus of Yirui Biological, a leading player in the domestic food safety rapid testing industry, emphasizing its shift towards food safety testing and animal diagnostics after divesting its less profitable IVD business [3][5]. Food Safety Rapid Testing - Yirui Biological has established a comprehensive testing system covering all aspects of the food supply chain, including feed, breeding, production, processing, distribution, and retail [3]. - The company has a significant advantage in dairy product testing, gradually replacing most imported products in the domestic market and receiving certifications from various international authorities [3]. - Continuous high R&D investment has led to the development of two major technological barriers: self-synthesis of antigens and antibodies, and efficient pre-treatment technology, with self-synthesis being the core barrier [3]. Animal Diagnostics - Initially focused on economic animal diagnostics, Yirui Biological is expanding into the pet diagnostics market, which is expected to contribute to future growth [4]. - The company plans to develop services related to pet geriatric disease prevention and vaccines, as well as extend into the pet consumer sector to create a diversified business ecosystem [4]. Strategic Partnerships - In April 2025, Yirui Biological signed a significant cooperation agreement with global biotech giant Chr. Hansen, valued at approximately 600 million yuan, focusing on dairy product testing [4]. - This partnership is seen as a milestone for the company's international expansion, with expectations for continued large orders and potential diversification into non-dairy products [4]. Investment Outlook - Yirui Biological is positioned as a leader in the domestic food safety rapid testing sector, with a strategic focus shift expected to enhance performance [5]. - The company forecasts net profits of 25 million yuan, 50 million yuan, and 70 million yuan for 2025-2027, representing year-on-year growth rates of 44.9%, 100.3%, and 40.2% respectively [5]. - A DCF model estimates the company's overall valuation at 6 billion yuan, with a target price of approximately 15 yuan, initiating coverage with a "recommended" rating [5].